Have a feature idea you'd love to see implemented?
Let us know!
ALGS Aligos Therapeutics Inc
Price (delayed)
$33.71
Market cap
$120.95M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$7.32
Enterprise value
$94.64M
Aligos Therapeutics, Inc. is a clinical stage biopharmaceutical company that was founded in 2018 with the mission to become a world leader in the treatment of viral infections and liver
Highlights
Aligos Therapeutics's EPS has soared by 84% YoY and by 50% from the previous quarter
The company's debt fell by 22% YoY and by 7% QoQ
ALGS's quick ratio is up by 14% year-on-year but it is down by 11% since the previous quarter
ALGS's gross profit has dropped by 63% year-on-year and by 25% since the previous quarter
ALGS's revenue has dropped by 63% year-on-year and by 25% since the previous quarter
Key stats
What are the main financial stats of ALGS
Market
Valuations
Earnings
Shares outstanding
3.59M
Market cap
$120.95M
Enterprise value
$94.64M
Price to earnings (P/E)
N/A
Price to book (P/B)
2.15
Price to sales (P/S)
35.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.78
Revenue
$6M
Gross profit
$6M
Net income
-$76.95M
EBIT
-$94.59M
EBITDA
-$91.86M
Free cash flow
-$85.11M
Per share
Balance sheet
Liquidity
EPS
-$7.32
EPS diluted
-$7.32
Free cash flow per share
-$13.57
Book value per share
$15.67
Revenue per share
$0.96
TBVPS
$14.1
Total assets
$88.43M
Total liabilities
$38.33M
Debt
$9.13M
Equity
$50.1M
Working capital
$58.87M
Debt to equity
0.18
Current ratio
3.81
Quick ratio
3.58
Net debt/EBITDA
0.29
Margins
Efficiency
Dividend
EBITDA margin
-1,531.8%
Gross margin
100%
Net margin
-1,283.2%
Operating margin
-1,577.3%
Return on assets
-64.6%
Return on equity
-114.3%
Return on invested capital
-200%
Return on capital employed
-140.2%
Return on sales
-1,577.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
ALGS stock price
How has the Aligos Therapeutics stock price performed over time
Intraday
-0.24%
1 week
6.24%
1 month
-15.39%
1 year
98.06%
YTD
-15.39%
QTD
-15.39%
Financial performance
How have Aligos Therapeutics's revenue and profit performed over time
Revenue
$6M
Gross profit
$6M
Operating income
-$94.59M
Net income
-$76.95M
Gross margin
100%
Net margin
-1,283.2%
The company's net margin has shrunk by 157% YoY and by 35% QoQ
ALGS's gross profit has dropped by 63% year-on-year and by 25% since the previous quarter
ALGS's revenue has dropped by 63% year-on-year and by 25% since the previous quarter
The operating margin has declined by 34% since the previous quarter
Growth
What is Aligos Therapeutics's growth rate over time
Valuation
What is Aligos Therapeutics stock price valuation
P/E
N/A
P/B
2.15
P/S
35.26
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
15.78
Aligos Therapeutics's EPS has soared by 84% YoY and by 50% from the previous quarter
The stock's price to book (P/B) is 35% more than its 5-year quarterly average of 1.6
Aligos Therapeutics's equity has decreased by 25% QoQ and by 9% YoY
ALGS's revenue has dropped by 63% year-on-year and by 25% since the previous quarter
Efficiency
How efficient is Aligos Therapeutics business performance
The company's return on invested capital has surged by 55% YoY and by 18% QoQ
Aligos Therapeutics's ROS has decreased by 34% from the previous quarter
The return on equity has declined by 10% year-on-year and by 3.3% since the previous quarter
ALGS's return on assets is up by 9% year-on-year
Dividends
What is ALGS's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for ALGS.
Financial health
How did Aligos Therapeutics financials performed over time
The total assets is 131% more than the total liabilities
The total liabilities is up by 24% year-on-year but it has declined by 8% since the previous quarter
The total assets has contracted by 19% from the previous quarter but it has grown by 3% YoY
The company's debt is 82% lower than its equity
Aligos Therapeutics's equity has decreased by 25% QoQ and by 9% YoY
The company's debt fell by 22% YoY and by 7% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.